TOFERSEN
Tofersen 100 mg/15 mL injection, 15 mL vial
TOFERSEN (15532L)
15532L
Body System:
Manner of administration:Injection
Restriction
Indication: Amyotrophic lateral sclerosis
Treatment phase: Subsequent continuing treatment
Restriction
Indication: Amyotrophic lateral sclerosis
Treatment phase: Grandfather arrangements - Transitioning from non-PBS to PBS-subsidised treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $28,400.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Qalsody | |||||